Literature DB >> 31644910

MALT1 Phosphorylation Controls Activation of T Lymphocytes and Survival of ABC-DLBCL Tumor Cells.

Torben Gehring1, Tabea Erdmann2, Marco Rahm3, Carina Graß1, Andrew Flatley4, Thomas J O'Neill1, Simone Woods1, Isabel Meininger1, Ozge Karayel5, Kerstin Kutzner1, Michael Grau2, Hisaaki Shinohara6, Katja Lammens7, Regina Feederle4, Stefanie M Hauck3, Georg Lenz2, Daniel Krappmann8.   

Abstract

The CARMA1/CARD11-BCL10-MALT1 (CBM) complex bridges T and B cell antigen receptor (TCR/BCR) ligation to MALT1 protease activation and canonical nuclear factor κB (NF-κB) signaling. Using unbiased mass spectrometry, we discover multiple serine phosphorylation sites in the MALT1 C terminus after T cell activation. Phospho-specific antibodies reveal that CBM-associated MALT1 is transiently hyper-phosphorylated upon TCR/CD28 co-stimulation. We identify a dual role for CK1α as a kinase that is essential for CBM signalosome assembly as well as MALT1 phosphorylation. Although MALT1 phosphorylation is largely dispensable for protease activity, it fosters canonical NF-κB signaling in Jurkat and murine CD4 T cells. Moreover, constitutive MALT1 phosphorylation promotes survival of activated B cell-type diffuse large B cell lymphoma (ABC-DLBCL) cells addicted to chronic BCR signaling. Thus, MALT1 phosphorylation triggers optimal NF-κB activation in lymphocytes and survival of lymphoma cells.
Copyright © 2019 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  B cell lymphomas; CBM complex; MALT1; NF-kappa B; T cell activation; adaptive immunity; antigen receptor signaling; casein kinase 1 alpha; immune response; phosphorylation

Year:  2019        PMID: 31644910     DOI: 10.1016/j.celrep.2019.09.040

Source DB:  PubMed          Journal:  Cell Rep            Impact factor:   9.423


  8 in total

1.  CARD11 alteration as a candidate biomarker of skin cutaneous melanoma treated with immune checkpoint blockade.

Authors:  Yutian Si; Anqi Lin; Weimin Ding; Hui Meng; Peng Luo; Jian Zhang
Journal:  Am J Transl Res       Date:  2021-01-15       Impact factor: 4.060

2.  In silico study on identification of novel MALT1 allosteric inhibitors.

Authors:  Jinrui Zhang; Li Ren; Ye Wang; Xuexun Fang
Journal:  RSC Adv       Date:  2019-11-29       Impact factor: 4.036

Review 3.  Druggable Sphingolipid Pathways: Experimental Models and Clinical Opportunities.

Authors:  Victoria A Blaho
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 4.  Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.

Authors:  Zaira Spinello; Anna Fregnani; Laura Quotti Tubi; Livio Trentin; Francesco Piazza; Sabrina Manni
Journal:  Int J Mol Sci       Date:  2021-04-02       Impact factor: 5.923

5.  Mechanistic impact of oligomer poisoning by dominant-negative CARD11 variants.

Authors:  Jacquelyn R Bedsaul; Neha Shah; Shelby M Hutcherson; Joel L Pomerantz
Journal:  iScience       Date:  2022-01-22

6.  A20 and ABIN-1 cooperate in balancing CBM complex-triggered NF-κB signaling in activated T cells.

Authors:  Hongli Yin; Ozge Karayel; Ying-Yin Chao; Thomas Seeholzer; Isabel Hamp; Oliver Plettenburg; Torben Gehring; Christina Zielinski; Matthias Mann; Daniel Krappmann
Journal:  Cell Mol Life Sci       Date:  2022-01-31       Impact factor: 9.261

7.  Methods to Study CARD11-BCL10-MALT1 Dependent Canonical NF-κB Activation in Jurkat T Cells.

Authors:  Andreas Gewies; Carina Graß; Daniel Krappmann
Journal:  Methods Mol Biol       Date:  2021

8.  Human immune disorder associated with homozygous hypomorphic mutation affecting MALT1B splice variant.

Authors:  Necil Kutukculer; Thomas Seeholzer; Thomas J O'Neill; Carina Graß; Ayca Aykut; Neslihan Edeer Karaca; Asude Durmaz; Ozgur Cogulu; Guzide Aksu; Torben Gehring; Andreas Gewies; Daniel Krappmann
Journal:  J Allergy Clin Immunol       Date:  2020-08-25       Impact factor: 10.793

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.